問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

邱鼎育
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

23Cases

2025-06-13 - 2030-06-30

Active
An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]
  • Condition/Disease

    Primary Membranous Nephropathy

  • Test Drug

    Injectable frozen powder

Participate Sites
10Sites

Recruiting10Sites

2020-04-01 - 2023-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Not yet recruiting9Sites

Terminated6Sites

2023-11-10 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2025-12-01 - 2027-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2021-08-31 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2024-10-03 - 2029-10-04

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-03-31 - 2024-08-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2022-05-02 - 2026-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-03-31 - 2022-11-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2022-01-05 - 2029-11-11

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

1 2 3